Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA.
-
Hou Y
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Pinheiro J
Department of Pathology, Centro Hospitalar São João, Porto, Portugal.
-
Sahm F
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Reuss DE
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Schrimpf D
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Stichel D
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Casalini B
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Koelsche C
Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Sievers P
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Wefers AK
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Reinhardt A
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Ebrahimi A
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Fernández-Klett F
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Pusch S
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Meier J
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Schweizer L
Department of Neuropathology, Charité, Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, and Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
-
Paulus W
Institute of Neuropathology, University Hospital Münster, Münster, Germany.
-
Prinz M
Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.
-
Hartmann C
Department of Neuropathology, Medizinische Hochschule Hannover, Hannover, Germany.
-
Plate KH
Department of Neuropathology, University Hospital Frankfurt, Frankfurt, Germany.
-
Reifenberger G
Department of Neuropathology, University Hospital Düsseldorf, Düsseldorf, Germany.
-
Pietsch T
Department of Neuropathology, University of Bonn, Bonn, Germany.
-
Varlet P
Department of Neuropathology, Hôpital Sainte-Anne, Université Paris V Descartes, Sorbonne Paris Cité, Paris, France.
-
Pagès M
Department of Neuropathology, Hôpital Sainte-Anne, Université Paris V Descartes, Sorbonne Paris Cité, Paris, France.
-
Schüller U
Department of Neuropathology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
-
Scheie D
Department of Pathology, Rigshospitalet, Copenhagen, Denmark.
-
de Stricker K
Department of Pathology, Rigshospitalet, Copenhagen, Denmark.
-
Frank S
Division of Neuropathology, Department of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
-
Hench J
Division of Neuropathology, Department of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
-
Pollo B
Department of Neuropathology, Neurological Institute Besta, Milan, Italy.
-
Brandner S
Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, and, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
-
Unterberg A
Division of Experimental Neurosurgery, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany.
-
Pfister SM
Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
-
Jones DTW
Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
-
Korshunov A
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
-
Wick W
Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
-
Capper D
Department of Neuropathology, Charité, Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin, and Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
-
Blümcke I
Department of Neuropathology, University Hospital Erlangen, Erlangen, Germany.
-
von Deimling A
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. andreas.vondeimling@med.uni-heidelberg.de.
-
Bertero L
Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Show more…
Published in:
- Acta neuropathologica. - 2019
English
Papillary glioneuronal tumor (PGNT) is a WHO-defined brain tumor entity that poses a major diagnostic challenge. Recently, SLC44A1-PRKCA fusions have been described in PGNT. We subjected 28 brain tumors from different institutions histologically diagnosed as PGNT to molecular and morphological analysis. Array-based methylation analysis revealed that 17/28 tumors exhibited methylation profiles typical for other tumor entities, mostly dysembryoplastic neuroepithelial tumor and hemispheric pilocytic astrocytoma. Conversely, 11/28 tumors exhibited a unique profile, thus constituting a distinct methylation class PGNT. By screening the extended Heidelberg cohort containing over 25,000 CNS tumors, we identified three additional tumors belonging to this methylation cluster but originally histologically diagnosed otherwise. RNA sequencing for the detection of SLC44A1-PRKCA fusions could be performed on 19 of the tumors, 10 of them belonging to the methylation class PGNT. In two additional cases, SLC44A1-PRKCA fusions were confirmed by FISH. We detected fusions involving PRKCA in all cases of this methylation class with material available for analyses: the canonical SLC44A1-PRKCA fusion was observed in 11/12 tumors, while the remaining case exhibited a NOTCH1-PRKCA fusion. Neither of the fusions was found in the tumors belonging to other methylation classes. Our results point towards a high misclassification rate of the morphological diagnosis PGNT and clearly demonstrate the necessity of molecular analyses. PRKCA fusions are highly diagnostic for PGNT, and detection by RNA sequencing enables the identification of rare fusion partners. Methylation analysis recognizes a unique methylation class PGNT irrespective of the nature of the PRKCA fusion.
-
Language
-
-
Open access status
-
green
-
Identifiers
-
-
Persistent URL
-
https://fredi.hepvs.ch/global/documents/17944
Statistics
Document views: 54
File downloads: